人参皂苷Rg3胶囊联合化疗治疗中晚期非小细胞肺癌的疗效观察  

Clinical efficacy of ginsenoside Rg3 combined with chemotherapy treatment on non - small - cell lung cancer

作　　者：王艳[1] 刘静蕾[1] 赵红丽[1] 杨茂鹏[1] 李欣[1] 刘莉[2] 

机构地区：[1]哈尔滨医科大学附属第三医院,哈尔滨150081 [2]黑龙江中医药大学

出　　处：《实用肿瘤学杂志》2011年第1期33-35,共3页Practical Oncology Journal

基　　金：黑龙江省自然科学基金D200849

摘　　要：目的观察人参皂苷Rg3对非小细胞肺癌患者血清VEGF水平及疗效的影响。方法选择ⅢB期不可手术切除的患者人组，实验组给予化疗同时口服Rg320mg，每日二次口服，用药2个疗程；对照组单纯给予化疗。用药结束后，观察患者血清VEGF、CEA水平变化情况，患者生活质量改善情况及毒副反应。结果用药2个疗程后，实验组患者血清VEGF水平明显下降为（315．7±15．2）pg／mL，CEA水平明显下降者占78％，生活质量KPs评分明显改善者为74．6％，毒副反应发生率明显减低，与对照组相比较均有显著性差异（P〈0．05）。结论对于ⅢB期不可手术切除非小细胞肺癌患者，给予化疗同时口服人参皂苷Rg3治疗，可抑制肿瘤新生血管的形成，增加抑瘤效果，改善患者生活质量。Objective To observe the effect of ginsenoside Rg3 （Shenyi capsule ）on serum level of VEGF and treatment efficacy on NSCLC patients. Methods NSCLC patients who were in ⅢB and could not conduct operations were selected. In experiment group, patients have been treated by chemotherapy combined with ginsenoside Rg3 taken orally ,20 mg per time, twice a day and continuously for 2 courses of treatment. In control group, patients have been treated only by chemotherapy. After treatment were completed, patients serum levels of VEGF, CEA, quality of life, toxicity and adverse effect were observed. Results After treatment were completed, compared with control group, serum levels of VECF and CEA decreased obviously（ P 〈 0.05 ）in experiment group and patients quality of life were improved obviously（ P 〈0.05）. The incidence of toxin and side effect in experiment group was obviously lower. Conclusion NSCLC patients who were in ⅢB and could not conduct operations accepting chemotherapy combined with ginsenoside Rg3 can inhibit tumor - related angiogenesis, increase the anti - tumor efficacy and improve the patients quality of life.

关 键 词：人参皂苷RG3 非小细胞肺癌 VEGF 

分 类 号：R734.2[医药卫生—肿瘤]